AEON
AEON Biopharma, Inc. AMEX$0.95
After hrs
$0.94
+2.00%
Mkt Cap $11.2M
52w Low $0.43
51.0% of range
52w High $1.45
50d MA $1.04
200d MA $0.95
P/E (TTM)
-0.2x
EV/EBITDA
-2.6x
P/B
—
Debt/Equity
-0.7x
ROE
197.4%
P/FCF
-0.6x
RSI (14)
—
ATR (14)
—
Beta
0.73
50d MA
$1.04
200d MA
$0.95
Avg Volume
103.5K
About
AEON Biopharma, Inc., a biopharmaceutical company, focuses on the development botulinum toxins for the treatment of debilitating medical conditions. It also develops 900 kDabotulinum toxin complex, ABP-450, for migraine, cervical dystonia, and gastroparesis. The company was formerly known as ALPHAEON Corporation and changed its name to AEON Biopharma, Inc. in December 2019. AEON Biopharma, Inc. wa…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 30, 2026 | AMC | -0.20 | -3.72 | -1714.6% | 0.99 | +21.3% | -0.5% | -1.1% | -10.2% | -8.0% | -5.3% | — |
| Nov 14, 2025 | AMC | -0.43 | -0.39 | +9.3% | 0.90 | -1.0% | -3.8% | +6.2% | +4.0% | -9.3% | -8.2% | — |
| Aug 12, 2025 | AMC | — | -0.60 | — | 0.69 | -2.9% | +16.1% | +13.2% | +11.5% | +9.6% | +6.1% | — |
| May 14, 2025 | AMC | -13.67 | -0.09 | +99.3% | 0.50 | -6.6% | -1.0% | +0.4% | +2.2% | +2.2% | -2.4% | — |
| Mar 24, 2025 | AMC | -12.95 | 3.75 | +129.0% | 0.72 | +2.2% | -7.3% | -3.3% | -11.6% | -18.1% | -19.9% | — |
| Nov 13, 2024 | AMC | -11.51 | -11.51 | +0.0% | 49.69 | +1.4% | -11.4% | -10.6% | -13.5% | -16.0% | -18.3% | — |
| Aug 12, 2024 | AMC | -13.67 | -11.51 | +15.8% | 71.99 | +4.0% | -1.0% | +1.0% | +5.0% | +2.0% | +0.0% | — |
| May 14, 2024 | AMC | -22.30 | -20.14 | +9.7% | 117.36 | +0.0% | -3.1% | -8.0% | -6.1% | +4.3% | +1.2% | — |
| Mar 29, 2024 | AMC | -0.40 | -0.71 | -77.5% | — | — | — | — | — | — | — | — |
| Jun 30, 2023 | AMC | — | -40.37 | — | — | — | — | — | — | — | — | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 8 | Aegis Capital | Maintains | Buy → Buy | — | $0.94 | $0.97 | +3.7% | -1.6% | +10.2% | +20.9% | +14.4% | +25.1% |
| Oct 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $75.60 | $75.60 | +0.0% | -2.9% | +7.6% | +5.7% | +15.2% | +42.9% |
| Aug 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $71.28 | $72.00 | +1.0% | +2.0% | +6.1% | +3.0% | +1.0% | +0.0% |
| Jul 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $79.20 | $77.40 | -2.3% | -5.5% | -3.6% | +27.3% | +107.3% | +160.0% |
| May 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $108.00 | $114.48 | +6.0% | -4.0% | +5.3% | +9.3% | +4.0% | +3.3% |
| May 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $117.36 | $117.36 | +0.0% | -3.1% | -8.0% | -6.1% | +4.3% | +1.2% |
| May 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $122.40 | $126.00 | +2.9% | -4.1% | -6.5% | +4.1% | -2.4% | +1.8% |
| Apr 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $496.08 | $493.20 | -0.6% | -1.5% | -5.1% | -32.4% | -31.5% | -37.6% |
Recent Filings
8-K
Unknown — 8-K Filing
AEON faces delisting risk if it fails to meet NYSE American's standards by August 2026, creating significant uncertainty for shareholders and potentially triggering forced selling pressure.
Apr 3
8-K
Unknown — 8-K Filing
AEON's biosimilar prabotulinumtoxin A advance toward full BOTOX market entry could unlock significant revenue from the multi-billion dollar aesthetics market, making clinical/regulatory progress critical for shareholders.
Mar 30
8-K · 5.02
!!! Very High
AEON Biopharma, Inc. -- 8-K 5.02: Executive Change
AEON Biopharma appointed John Bencich as Chief Financial Officer, signaling leadership changes that could affect the company's financial strategy and investor confidence going forward.
Mar 9
Data updated apr 24, 2026 4:18pm
· Source: massive.com